Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry
Background: Documenting the patterns of oral anticoagulation therapy (OAT) is essential to prevent thromboembolic complications of nonvalvular atrial fibrillation (NVAF). Objective: To report the patterns of OAT according to age and thromboembolic risk in patients included in CARMEN-AF, a nationwide...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Ubiquity Press
2020-04-01
|
Series: | Global Heart |
Subjects: | |
Online Access: | https://globalheartjournal.com/articles/767 |
_version_ | 1819111884583862272 |
---|---|
author | Manlio F. Márquez Manuel A. Baños-González Milton E. Guevara-Valdivia Jorge Vázquez-Acosta Manuel O. de los Ríos Ibarra Julio A. Aguilar-Linares Marcelo Jiménez-Cruz Norberto Matadamas-Hernández Rocío Camacho-Casillas Reynaldo Magaña-Magaña Ulises Rojel-Martínez Marco A. Alcocer-Gamba Susano Lara-Vaca Humberto Rodríguez-Reyes Marco A. Islava-Gálvez Lidia E. Betancourt-Hernández Nicolás Reyes-Reyes Miguel E. Beltrán-Gámez Carlos Cantú-Brito Alberto Z. Baños-Velasco Pedro J. del Rivero Morfin J. Antonio González-Hermosillo |
author_facet | Manlio F. Márquez Manuel A. Baños-González Milton E. Guevara-Valdivia Jorge Vázquez-Acosta Manuel O. de los Ríos Ibarra Julio A. Aguilar-Linares Marcelo Jiménez-Cruz Norberto Matadamas-Hernández Rocío Camacho-Casillas Reynaldo Magaña-Magaña Ulises Rojel-Martínez Marco A. Alcocer-Gamba Susano Lara-Vaca Humberto Rodríguez-Reyes Marco A. Islava-Gálvez Lidia E. Betancourt-Hernández Nicolás Reyes-Reyes Miguel E. Beltrán-Gámez Carlos Cantú-Brito Alberto Z. Baños-Velasco Pedro J. del Rivero Morfin J. Antonio González-Hermosillo |
author_sort | Manlio F. Márquez |
collection | DOAJ |
description | Background: Documenting the patterns of oral anticoagulation therapy (OAT) is essential to prevent thromboembolic complications of nonvalvular atrial fibrillation (NVAF). Objective: To report the patterns of OAT according to age and thromboembolic risk in patients included in CARMEN-AF, a nationwide registry of NVAF in Mexico, an upper middle-income country. Material and methods: There were 1,423 consecutive patients =18 years old and with at least one thromboembolic risk factor enrolled in the CARMEN-AF Registry at their regular clinical visit during a three-year period. They were analyzed according to 1) age, 2) AF type, and 3) CHA2DS2-VASc score. Results: Overall, 16.4% of patients did not receive antithrombotic treatment, 19.4% received antiplatelet drugs (APD), 29.2% vitamin K antagonists (VKA), and 34.6% direct oral anticoagulants (DOAC). With increasing age, the proportion of subjects treated with VKA decreased significantly from 36.2% in subjects 2DS2-VASc =2) compared with the moderate risk group (41% in CHA2DS2-VASc = 1). Conclusions: VKA use for NVAF in Mexico decreased in relation to increasing age. The proportion of DOAC therapy was the same in all age groups. Nevertheless, elderly patients with high thromboembolic risk received a suboptimal thromboprophylaxis. These data could help to improve gaps in the implementation of global guidelines. Clinical trial registration: http://www.clinicaltrials.gov. Unique identifier: NCT02334852. Highlights: CARMEN-AF is a nationwide multi-centric registry seeking to bridge the data gap on anticoagulation therapy for NVAF in Mexico. Elderly patients are more prone to receive suboptimal OAT for NVAF. DOAC were less frequently used in high thromboembolic risk patients (CHA2DS2-VASc =2). |
first_indexed | 2024-12-22T04:04:42Z |
format | Article |
id | doaj.art-84bda2ed76fd4339abb1ca0b2beaa603 |
institution | Directory Open Access Journal |
issn | 2211-8179 |
language | English |
last_indexed | 2024-12-22T04:04:42Z |
publishDate | 2020-04-01 |
publisher | Ubiquity Press |
record_format | Article |
series | Global Heart |
spelling | doaj.art-84bda2ed76fd4339abb1ca0b2beaa6032022-12-21T18:39:40ZengUbiquity PressGlobal Heart2211-81792020-04-0115110.5334/gh.767762Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF RegistryManlio F. Márquez0Manuel A. Baños-González1Milton E. Guevara-Valdivia2Jorge Vázquez-Acosta3Manuel O. de los Ríos Ibarra4Julio A. Aguilar-Linares5Marcelo Jiménez-Cruz6Norberto Matadamas-Hernández7Rocío Camacho-Casillas8Reynaldo Magaña-Magaña9Ulises Rojel-Martínez10Marco A. Alcocer-Gamba11Susano Lara-Vaca12Humberto Rodríguez-Reyes13Marco A. Islava-Gálvez14Lidia E. Betancourt-Hernández15Nicolás Reyes-Reyes16Miguel E. Beltrán-Gámez17Carlos Cantú-Brito18Alberto Z. Baños-Velasco19Pedro J. del Rivero Morfin20J. Antonio González-Hermosillo21Instituto Nacional de Cardiología Ignacio ChávezCentro de Investigación y Posgrado, División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco (UJAT)Unidad Médica de Alta Especialidad del Hospital de Especialidades “Dr. Antonio Fraga Mouret”, Centro Médico Nacional “La Raza”, Instituto Mexicano del Seguro SocialHospital Regional de PEMEX Ciudad MaderoSINACOR, Centro para el Desarrollo de la Medicina y de Asistencia Médica Especializada S.C.Hospital Regional No.1 Tijuana, Instituto Mexicano del Seguro SocialHospital de Cardiología, Centro Médico Nacional “Siglo XXI”, Instituto Mexicano del Seguro SocialHospital General de AcapulcoUnidad Médica de Alta Especialidad No. 71, Instituto Mexicano del Seguro SocialHospital General de Uruapan “Dr. Pedro Daniel Martínez”Hospital General del Sur de Puebla “Eduardo Vázquez Navarro”Instituto de Corazón de QuerétaroHospital Ángeles LeónSociedad Cardiovascular y ArritmiasInstituto Mexicano de TrasplantesUnidad Médica de Alta Especialidad No. 14, Instituto Mexicano del Seguro SocialHospital Ángeles PueblaHospital Ángeles TijuanaDepartamento de Neurología, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”Hospital Ángeles CuliacánInstituto Nacional de Cardiología Ignacio ChávezInstituto Nacional de Cardiología Ignacio ChávezBackground: Documenting the patterns of oral anticoagulation therapy (OAT) is essential to prevent thromboembolic complications of nonvalvular atrial fibrillation (NVAF). Objective: To report the patterns of OAT according to age and thromboembolic risk in patients included in CARMEN-AF, a nationwide registry of NVAF in Mexico, an upper middle-income country. Material and methods: There were 1,423 consecutive patients =18 years old and with at least one thromboembolic risk factor enrolled in the CARMEN-AF Registry at their regular clinical visit during a three-year period. They were analyzed according to 1) age, 2) AF type, and 3) CHA2DS2-VASc score. Results: Overall, 16.4% of patients did not receive antithrombotic treatment, 19.4% received antiplatelet drugs (APD), 29.2% vitamin K antagonists (VKA), and 34.6% direct oral anticoagulants (DOAC). With increasing age, the proportion of subjects treated with VKA decreased significantly from 36.2% in subjects 2DS2-VASc =2) compared with the moderate risk group (41% in CHA2DS2-VASc = 1). Conclusions: VKA use for NVAF in Mexico decreased in relation to increasing age. The proportion of DOAC therapy was the same in all age groups. Nevertheless, elderly patients with high thromboembolic risk received a suboptimal thromboprophylaxis. These data could help to improve gaps in the implementation of global guidelines. Clinical trial registration: http://www.clinicaltrials.gov. Unique identifier: NCT02334852. Highlights: CARMEN-AF is a nationwide multi-centric registry seeking to bridge the data gap on anticoagulation therapy for NVAF in Mexico. Elderly patients are more prone to receive suboptimal OAT for NVAF. DOAC were less frequently used in high thromboembolic risk patients (CHA2DS2-VASc =2).https://globalheartjournal.com/articles/767atrial fibrillationembolic riskanticoagulation therapyantithrombotic treatmentvitamin k antagonistdirect oral anticoagulantmexico |
spellingShingle | Manlio F. Márquez Manuel A. Baños-González Milton E. Guevara-Valdivia Jorge Vázquez-Acosta Manuel O. de los Ríos Ibarra Julio A. Aguilar-Linares Marcelo Jiménez-Cruz Norberto Matadamas-Hernández Rocío Camacho-Casillas Reynaldo Magaña-Magaña Ulises Rojel-Martínez Marco A. Alcocer-Gamba Susano Lara-Vaca Humberto Rodríguez-Reyes Marco A. Islava-Gálvez Lidia E. Betancourt-Hernández Nicolás Reyes-Reyes Miguel E. Beltrán-Gámez Carlos Cantú-Brito Alberto Z. Baños-Velasco Pedro J. del Rivero Morfin J. Antonio González-Hermosillo Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry Global Heart atrial fibrillation embolic risk anticoagulation therapy antithrombotic treatment vitamin k antagonist direct oral anticoagulant mexico |
title | Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry |
title_full | Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry |
title_fullStr | Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry |
title_full_unstemmed | Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry |
title_short | Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry |
title_sort | anticoagulation therapy by age and embolic risk for nonvalvular atrial fibrillation in mexico an upper middle income country the carmen af registry |
topic | atrial fibrillation embolic risk anticoagulation therapy antithrombotic treatment vitamin k antagonist direct oral anticoagulant mexico |
url | https://globalheartjournal.com/articles/767 |
work_keys_str_mv | AT manliofmarquez anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT manuelabanosgonzalez anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT miltoneguevaravaldivia anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT jorgevazquezacosta anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT manuelodelosriosibarra anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT julioaaguilarlinares anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT marcelojimenezcruz anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT norbertomatadamashernandez anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT rociocamachocasillas anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT reynaldomaganamagana anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT ulisesrojelmartinez anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT marcoaalcocergamba anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT susanolaravaca anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT humbertorodriguezreyes anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT marcoaislavagalvez anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT lidiaebetancourthernandez anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT nicolasreyesreyes anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT miguelebeltrangamez anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT carloscantubrito anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT albertozbanosvelasco anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT pedrojdelriveromorfin anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry AT jantoniogonzalezhermosillo anticoagulationtherapybyageandembolicriskfornonvalvularatrialfibrillationinmexicoanuppermiddleincomecountrythecarmenafregistry |